Just a month after Bo Jesper Hansen was named as chairman of the board of Belgian biotech Ablynx, his resignation has been announced.
Dr Hansen, a former executive chairman of Swedish biotech SOBI (Swedish Orphan Biovitrum), is the latest to jump ship as Ablynx prepares for life under the ownership of a pharma big boy.
"My goal will be to fully support the proposed acquisition of the company by Sanofi, as recommended by the Ablynx board"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze